What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
Feb. 3 |
Weekly Gain |
My Watchlist |
|---|---|---|---|
|
BroadVision |
$34.14 | 61% | Add |
|
Corinthian Colleges |
$4.59 | 56% | Add |
|
Affymax |
$10.38 | 43% | Add |
|
Amylin Pharmaceuticals |
$17.10 | 41% | Add |
|
RealD |
$12.23 | 36% | Add |
Source: Barron's.
BroadVision was last week's biggest winner. There wasn't any improvement in the company's fundamentals to account for the 61% pop, though the stock did bounce back after posting uninspiring quarterly results on Thursday of the prior week. Fellow Fool Sean Williams suspects that a notorious stock promoter is pumping the shares of the provider of e-commerce and business social networking solutions.
Me? I thought BroadVision made beer goggles.
Corinthian Colleges moved to the head of the class after posting better-than-expected financial results. The for-profit post-secondary educator had posted its first quarterly loss in years three months ago. Investors are glad to see Corinthian back on track.
Upstart biotech Affymax had a strong week. Outside of an executive promotion, there wasn't a lot of news on the company.
Amylin Pharmaceuticals saw its shares pop after the FDA cleared the drugmaker's new diabetes treatment. Bydureon is an enhanced form of Amylin's currently marketed twice-a-day injectable drug Byetta that only needs to be administered once a week.
Finally, we have RealD screening better-than-expected results in its latest quarter. The 3-D outfitter now has an installed base of 19,700 theaters using its 3-D projectors.
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
